Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Neuroimmune activation as a novel therapeutic approach for IBD

Objetivo

NeurIMM has been designed to investigate the commercial and technical viability of a novel, targeted therapy for Inflammatory Bowel Disease (IBD), based on a recently uncovered signaling axis between intestinal type 3 innate lymphoid cells (ILC3s) and enteric glial cells. This discovery by the team of Prof. Henrique Veiga-Fernandes in the ERC CoG grant 647274 ‘GliaInnateSensing’ was recently published in Nature (Ibiza et al, Nature 2016). NeurIMM proposes the use of a glial cell-derived immunomodulator to restore intestinal homeostasis, by inducing a tissue protective immune response. Importantly, this novel therapy will also promote tissue healing to reverse immune-cell mediated tissue damage, leading to improved outcomes for the patient. This could have major implications for patients suffering from IBD. In addition, this approach also has potential as an effective therapy against cancer, (pediatric) gastroenteritis, and other inflammatory disorders.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Régimen de financiación

ERC-POC - Proof of Concept Grant

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2017-PoC

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD
Aportación neta de la UEn
€ 150 000,00
Coste total
€ 150 000,00

Beneficiarios (1)